LEADER 02272nam  2200541   450 
001 9910792288003321
005 20230803024252.0
010   $a1-78084-189-2
035   $a(CKB)2560000000152109
035   $a(EBL)1179648
035   $a(SSID)ssj0001599933
035   $a(PQKBManifestationID)16306834
035   $a(PQKBTitleCode)TC0001599933
035   $a(PQKBWorkID)14892902
035   $a(PQKB)10768650
035   $a(MiAaPQ)EBC1179648
035   $a(Au-PeEL)EBL1179648
035   $a(OCoLC)877767242
035   $a(EXLCZ)992560000000152109
100   $a20220517d2013      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aGout /$feditors, Nicola Dalbeth, Fernando Perez-Ruiz, Naomi Schlesinger
205   $a1st ed.
210  1$aLondon, England :$cFuture Medicine Ltd.,$d[2013]
210  4$dİ2013
215   $a1 online resource (246 p.)
300   $aDescription based upon print version of record.
311   $a1-78084-191-4 
327   $aTitle page; Copyright page; Contents; Foreword. Gout; 1. Epidemiology of gout; 2. Pathological basis of hyperuricemia and gout; 3. Pathophysiology and immunology of acute and chronic gout; 4. An update on the genetic causes of hyperuricemia and gout; 5. Clinical features of gout; 6. Synovial fluid analysis and crystal identification; 7. Imaging of gout; 8. Outcome measures in gout; 9. The patient's perspective of gout; 10. Asymptomatic hyperuricemia and its clinical implications for extra-articular disease; 11. Principles of gout management
327   $a12. Urate-lowering therapy: xanthine oxidase inhibitors13. Urate-lowering therapy: uricosurics; 14. Urate-lowering therapy: uricases; 15. Therapies for acute flares and gout flare prophylaxis; 16. Gout comorbidities: prevalence and management; 17. Emerging therapeutics for acute and chronic gout; Index
330   $aGout
606   $aGout
615  0$aGout.
676   $a616.3999
702   $aDalbeth$b Nicola
702   $aPerez-Ruiz$b Fernando
702   $aSchlesinger$b Naomi
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910792288003321
996   $aGout$93851826
997   $aUNINA